CD63 and melanocytic neoplasm: Five additional RASGRF1 fusions have also been reported from NSCLC (TMEM87A-RASGRF1)19, acute myeloid leukemia (TMEM154-RASGRF1)23, melanoma (ABC22-RASGRF1)20, and melanocytic neoplasms with spitzoid features (CD63-RASGRF1 and EHBP1-RASGRF1)20.